FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060758966> ?p ?o ?g. }

• W2060758966 endingPage "275" @default.
• W2060758966 startingPage "267" @default.
• W2060758966 abstract "Afatinib, an oral irreversible ErbB family blocker, undergoes minimal metabolism by non-enzyme-catalysed adduct formation with proteins or nucleophilic small molecules and is predominantly non-renally excreted via the entero-hepatic system. This trial assessed whether mild or moderate hepatic impairment influences the pharmacokinetics of afatinib. This was an open-label single-dose study. Pharmacokinetic parameters after afatinib 50 mg were investigated in subjects with mild (n = 8) or moderate (n = 8) hepatic impairment (Child-Pugh A and B) and healthy controls (n = 16) matched for age, weight and gender. Plasma and urine samples for pharmacokinetic assessment were collected before and up to 10 days after dosing. Additional blood samples were drawn to determine ex vivo plasma protein binding of afatinib. Primary endpoints were comparisons of afatinib C max and AUC0–∞ between subjects with hepatic impairment and healthy matched controls. Study progression was based on drug-related toxicity (CTCAE v. 3.0) and C max of afatinib. Afatinib pharmacokinetic profiles and plasma protein binding were similar in subjects with impaired liver function and healthy controls. Compared with matched controls, the afatinib-adjusted geometric mean ratio for AUC0–∞ was 92.6 % (90 % CI 68.0–126.3 %) and C max was 109.5 % (90 % CI 82.7–144.9 %) for subjects with mild hepatic impairment, and 94.9 % (90 % CI 72.3–124.5 %) and 126.9 % (90 % CI 86.0–187.2 %), respectively, for subjects with moderate hepatic impairment. For all parameters, the 90 % CI included 100 %. Afatinib was generally well tolerated with no serious adverse events reported. Mild to moderate hepatic impairment had no clinically relevant effect on the pharmacokinetics of a single 50 mg dose of afatinib, implying that adjustments to the starting dose of afatinib are not considered necessary in this patient population." @default.
• W2060758966 created "2016-06-24" @default.
• W2060758966 creator A5009812253 @default.
• W2060758966 creator A5011225110 @default.
• W2060758966 creator A5011239601 @default.
• W2060758966 creator A5011928554 @default.
• W2060758966 creator A5016032936 @default.
• W2060758966 creator A5039917291 @default.
• W2060758966 creator A5042838066 @default.
• W2060758966 creator A5044081105 @default.
• W2060758966 creator A5052219607 @default.
• W2060758966 creator A5056192984 @default.
• W2060758966 creator A5059651725 @default.
• W2060758966 date "2014-06-07" @default.
• W2060758966 modified "2023-09-25" @default.
• W2060758966 title "Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment" @default.
• W2060758966 cites W1970807670 @default.
• W2060758966 cites W2036523295 @default.
• W2060758966 cites W2060123467 @default.
• W2060758966 cites W2062869295 @default.
• W2060758966 cites W2063391304 @default.
• W2060758966 cites W2096198395 @default.
• W2060758966 cites W2114095518 @default.
• W2060758966 cites W2118186702 @default.
• W2060758966 cites W2126696135 @default.
• W2060758966 cites W2138851777 @default.
• W2060758966 cites W2152905269 @default.
• W2060758966 cites W2153156618 @default.
• W2060758966 cites W2160336497 @default.
• W2060758966 cites W2171139285 @default.
• W2060758966 doi "https://doi.org/10.1007/s00280-014-2484-y" @default.
• W2060758966 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4112049" @default.
• W2060758966 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24906422" @default.
• W2060758966 hasPublicationYear "2014" @default.
• W2060758966 type Work @default.
• W2060758966 sameAs 2060758966 @default.
• W2060758966 citedByCount "35" @default.
• W2060758966 countsByYear W20607589662014 @default.
• W2060758966 countsByYear W20607589662015 @default.
• W2060758966 countsByYear W20607589662016 @default.
• W2060758966 countsByYear W20607589662017 @default.
• W2060758966 countsByYear W20607589662018 @default.
• W2060758966 countsByYear W20607589662019 @default.
• W2060758966 countsByYear W20607589662020 @default.
• W2060758966 countsByYear W20607589662021 @default.
• W2060758966 countsByYear W20607589662022 @default.
• W2060758966 countsByYear W20607589662023 @default.
• W2060758966 crossrefType "journal-article" @default.
• W2060758966 hasAuthorship W2060758966A5009812253 @default.
• W2060758966 hasAuthorship W2060758966A5011225110 @default.
• W2060758966 hasAuthorship W2060758966A5011239601 @default.
• W2060758966 hasAuthorship W2060758966A5011928554 @default.
• W2060758966 hasAuthorship W2060758966A5016032936 @default.
• W2060758966 hasAuthorship W2060758966A5039917291 @default.
• W2060758966 hasAuthorship W2060758966A5042838066 @default.
• W2060758966 hasAuthorship W2060758966A5044081105 @default.
• W2060758966 hasAuthorship W2060758966A5052219607 @default.
• W2060758966 hasAuthorship W2060758966A5056192984 @default.
• W2060758966 hasAuthorship W2060758966A5059651725 @default.
• W2060758966 hasBestOaLocation W20607589661 @default.
• W2060758966 hasConcept C112705442 @default.
• W2060758966 hasConcept C121608353 @default.
• W2060758966 hasConcept C126322002 @default.
• W2060758966 hasConcept C134018914 @default.
• W2060758966 hasConcept C22979827 @default.
• W2060758966 hasConcept C2777288759 @default.
• W2060758966 hasConcept C2778087573 @default.
• W2060758966 hasConcept C2779438470 @default.
• W2060758966 hasConcept C2780586478 @default.
• W2060758966 hasConcept C71924100 @default.
• W2060758966 hasConcept C90924648 @default.
• W2060758966 hasConcept C98274493 @default.
• W2060758966 hasConceptScore W2060758966C112705442 @default.
• W2060758966 hasConceptScore W2060758966C121608353 @default.
• W2060758966 hasConceptScore W2060758966C126322002 @default.
• W2060758966 hasConceptScore W2060758966C134018914 @default.
• W2060758966 hasConceptScore W2060758966C22979827 @default.
• W2060758966 hasConceptScore W2060758966C2777288759 @default.
• W2060758966 hasConceptScore W2060758966C2778087573 @default.
• W2060758966 hasConceptScore W2060758966C2779438470 @default.
• W2060758966 hasConceptScore W2060758966C2780586478 @default.
• W2060758966 hasConceptScore W2060758966C71924100 @default.
• W2060758966 hasConceptScore W2060758966C90924648 @default.
• W2060758966 hasConceptScore W2060758966C98274493 @default.
• W2060758966 hasIssue "2" @default.
• W2060758966 hasLocation W20607589661 @default.
• W2060758966 hasLocation W20607589662 @default.
• W2060758966 hasLocation W20607589663 @default.
• W2060758966 hasLocation W20607589664 @default.
• W2060758966 hasOpenAccess W2060758966 @default.
• W2060758966 hasPrimaryLocation W20607589661 @default.
• W2060758966 hasRelatedWork W2064759457 @default.
• W2060758966 hasRelatedWork W2370929226 @default.
• W2060758966 hasRelatedWork W2379280247 @default.
• W2060758966 hasRelatedWork W2766550598 @default.
• W2060758966 hasRelatedWork W2942467058 @default.
• W2060758966 hasRelatedWork W2945264506 @default.
• W2060758966 hasRelatedWork W3018168093 @default.

• next